Save your place

Sign in to WhoBought

Please try again later.

Tyra Biosciences, Inc. (TYRA) institutional ownership

Latest close $31.85 Jul 21, 2026
Market cap$551M 52-week range SectorHealthcare
Funds holding · Q1 2026
148
reported TYRA position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
98 buyers · 50 sellers

Tyra Biosciences, Inc. (TYRA) price and institutional activity

Dates

Q1 2026

$0 bought by 98 investors
FMR LLCParadigm Biocapital Advisors LP +96 more
$0 sold by 50 investors
Canaan Partners Xi LLCVestal Point Capital, LP +48 more
Bought Sold Totals per quarter; hover a bar for the names.

Tyra Biosciences, Inc. (TYRA) institutional activity · 148

Investor Type Est. change Change Δ Own Date
FMR LLC · Added
Change +7.7M Δ Own +61570.4% Date Q1 2026
FMR LLC Added· Q1 2026 +7.7M +61570.4% Q1 2026
Canaan Partners Xi LLC · Reduced
Change −2.6M Date Q1 2026
Canaan Partners Xi LLC Reduced· Q1 2026 −2.6M Q1 2026
Vestal Point Capital, LP · Reduced
Change −2.4M Date Q1 2026
Vestal Point Capital, LP Reduced· Q1 2026 −2.4M Q1 2026
Paradigm Biocapital Advisors LP · New
Change +2.1M Date Q1 2026
Paradigm Biocapital Advisors LP New· Q1 2026 +2.1M Q1 2026
Kynam Capital Management, LP · Exited
Change −1.6M Δ Own −100.0% Date Q1 2026
Kynam Capital Management, LP Exited· Q1 2026 −1.6M −100.0% Q1 2026
Farallon Capital Management LLC · Added
Change +1.5M Δ Own +73.3% Date Q1 2026
Farallon Capital Management LLC Added· Q1 2026 +1.5M +73.3% Q1 2026
T. Rowe Price Associates · Added
Change +972K Date Q1 2026
T. Rowe Price Associates Added· Q1 2026 +972K Q1 2026
Janus Henderson Group PLC · Added
Change +955K Date Q1 2026
Janus Henderson Group PLC Added· Q1 2026 +955K Q1 2026
Commodore Capital LP · Reduced
Change −900K Date Q1 2026
Commodore Capital LP Reduced· Q1 2026 −900K Q1 2026
Point72 Asset Management, L.P. · Reduced
Change −835K Δ Own −95.6% Date Q1 2026
Point72 Asset Management, L.P. Reduced· Q1 2026 −835K −95.6% Q1 2026
Barclays PLC · Added
Change +757K Date Q1 2026
Barclays PLC Added· Q1 2026 +757K Q1 2026
Trails Edge Capital Partners, LP · Exited
Change −700K Δ Own −100.0% Date Q1 2026
Trails Edge Capital Partners, LP Exited· Q1 2026 −700K −100.0% Q1 2026
Logos Global Management LP · Added
Change +640K Date Q1 2026
Logos Global Management LP Added· Q1 2026 +640K Q1 2026
Jennison Associates LLC · New
Change +632K Date Q1 2026
Jennison Associates LLC New· Q1 2026 +632K Q1 2026
Deerfield Management Company, L.P. · New
Change +549K Date Q1 2026
Deerfield Management Company, L.P. New· Q1 2026 +549K Q1 2026
Data through Q1 2026 · filed Jun 4, 2026
15 of 148

Famous investor activity in Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (TYRA) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Ra Capital Management, L.P. · Director Grant (A) 13K
Owned 13K Trade date May 28, 2026 Filed date Jun 1, 2026
Ra Capital Management, L.P. Director Grant (A) 13K 13K May 28, 2026 Jun 1, 2026
Verjee Rehan · Director Grant (A) 13K
Owned 13K Trade date May 28, 2026 Filed date Jun 1, 2026
Verjee Rehan Director Grant (A) 13K 13K May 28, 2026 Jun 1, 2026
Moran Susan · Director Grant (A) 13K
Owned 13K Trade date May 28, 2026 Filed date Jun 1, 2026
Moran Susan Director Grant (A) 13K 13K May 28, 2026 Jun 1, 2026
Simson Jake · Director Grant (A) 13K
Owned 13K Trade date May 28, 2026 Filed date Jun 1, 2026
Simson Jake Director Grant (A) 13K 13K May 28, 2026 Jun 1, 2026
Gulfo Adele M. · Director Grant (A) 13K
Owned 13K Trade date May 28, 2026 Filed date Jun 1, 2026
Gulfo Adele M. Director Grant (A) 13K 13K May 28, 2026 Jun 1, 2026
More Robert J. · Director Grant (A) 13K
Owned 13K Trade date May 28, 2026 Filed date Jun 1, 2026
More Robert J. Director Grant (A) 13K 13K May 28, 2026 Jun 1, 2026
Rothenberg Stephen Michael · Director Grant (A) 13K
Owned 13K Trade date May 28, 2026 Filed date Jun 1, 2026
Rothenberg Stephen Michael Director Grant (A) 13K 13K May 28, 2026 Jun 1, 2026
Warner Douglas J. · Officer 2 operations 110K
Owned 85K Trade date May 5, 2026 Filed date May 7, 2026
Warner Douglas J. Officer 2 operations 110K 85K May 5, 2026 May 7, 2026
Fuhrman Alan · CFO 2 operations 87K
Owned 67K Trade date May 5, 2026 Filed date May 7, 2026
Fuhrman Alan CFO 2 operations 87K 67K May 5, 2026 May 7, 2026
Harris Todd · Director 2 operations 344K
Owned 265K Trade date May 5, 2026 Filed date May 7, 2026
Harris Todd Director 2 operations 344K 265K May 5, 2026 May 7, 2026
Ashar Bhavesh · Officer 2 operations 65K
Owned 50K Trade date May 5, 2026 Filed date May 7, 2026
Ashar Bhavesh Officer 2 operations 65K 50K May 5, 2026 May 7, 2026
Rueb Yuliya · Officer 2 operations 36K
Owned 28K Trade date May 5, 2026 Filed date May 7, 2026
Rueb Yuliya Officer 2 operations 36K 28K May 5, 2026 May 7, 2026
Dable Habib J. · Director Grant (A) 44K
Owned 44K Trade date Apr 16, 2026 Filed date Apr 20, 2026
Dable Habib J. Director Grant (A) 44K 44K Apr 16, 2026 Apr 20, 2026
Kaplan Gilla · Director 2 operations -106K
Price $2.25 Owned 0 Trade date Mar 26, 2026 Filed date Mar 27, 2026
Kaplan Gilla Director 2 operations $2.25 -106K 0 Mar 26, 2026 Mar 27, 2026
Kaplan Gilla · Director Shares transferred outside the market (D), often for tax or as a gift, not a market sale -$2.0M
Price $37.75 Qty -53K Owned 28K Trade date Mar 26, 2026 Filed date Mar 27, 2026
Kaplan Gilla Director Shares transferred outside the market (D), often for tax or as a gift, not a market sale $37.75 -53K -$2.0M 28K Mar 26, 2026 Mar 27, 2026
15 of 35
15 of 35 Sign in to continue to older insider transactions.

Tyra Biosciences, Inc. (TYRA) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Ra Capital Management, L.P. 10.7M
% of shares outstanding 21.1% Filing date Nov 13, 2024
Ra Capital Management, L.P. 10.7M 21.1% Nov 13, 2024
Nextech VI Oncology Scsp 4.1M
% of shares outstanding 7.7% Filing date Nov 14, 2024
Nextech VI Oncology Scsp 4.1M 7.7% Nov 14, 2024
Janus Henderson Group PLC 3.9M
% of shares outstanding 7.2% Filing date May 15, 2026
Janus Henderson Group PLC 3.9M 7.2% May 15, 2026
FMR LLC 3.4M
% of shares outstanding 6.4% Filing date Nov 12, 2024
FMR LLC 3.4M 6.4% Nov 12, 2024
Todd Harris 2.9M
% of shares outstanding 4.8% Filing date May 14, 2026
Todd Harris 2.9M 4.8% May 14, 2026
Biotechnology Value Fund L P 2.4M
% of shares outstanding 4.6% Filing date Nov 14, 2024
Biotechnology Value Fund L P 2.4M 4.6% Nov 14, 2024
Commodore Capital LP 2.5M
% of shares outstanding 4.2% Filing date May 15, 2026
Commodore Capital LP 2.5M 4.2% May 15, 2026
Canaan Xi L.P. 750K
% of shares outstanding 1.4% Filing date Apr 24, 2026
Canaan Xi L.P. 750K 1.4% Apr 24, 2026
8 of 12

Tyra Biosciences, Inc. (TYRA) ownership FAQ

Who owns TYRA?

148 reporting institutions disclosed TYRA position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.